Humacyte, Inc. - Common Stock (NQ:HUMA)

0.4354 +0.0223 (+5.40%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Humacyte Earnings Preview ↗

August 11, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗

June 22, 2023

Via Benzinga

Earnings Scheduled For May 12, 2023 ↗

May 12, 2023

Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

Via Benzinga

Recap: Humacyte Q1 Earnings ↗

May 12, 2023

Via Benzinga

Earnings Outlook For Humacyte ↗

May 11, 2023

Via Benzinga

Earnings Preview For Humacyte ↗

March 23, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

February 13, 2023

Via Benzinga

Earnings Scheduled For March 24, 2023 ↗

March 24, 2023

Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth...

Via Benzinga

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

March 24, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023

March 21, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

February 27, 2023

From Humacyte, Inc

Via GlobeNewswire

5 Value Stocks In The Healthcare Sector ↗

December 26, 2022

Via Benzinga

Humacyte's Return on Invested Capital Insights ↗

December 19, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 13, 2023

Via Benzinga

Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease

January 24, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime

December 13, 2022

Thursday, December 15, 2022 @ 8:00 AM ET

From Humacyte, Inc

Via GlobeNewswire

Sidoti's December Small-Cap Virtual Conference

December 06, 2022

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Wednesday ↗

December 14, 2022

On Wednesday, 115 stocks hit new 52-week lows.

Via Benzinga

Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022

December 01, 2022

Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

November 23, 2022

From Humacyte, Inc

Via GlobeNewswire

Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday ↗

November 21, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 16, 2022

On Wednesday, 70 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 15, 2022

On Tuesday, 34 companies set new 52-week lows.

Via Benzinga

Humacyte Third Quarter 2022 Financial Results and Business Update

November 10, 2022

From Humacyte, Inc

Via GlobeNewswire

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting

November 07, 2022

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022

November 03, 2022

From Humacyte, Inc

Via GlobeNewswire

Livent, Amgen And Some Other Big Stocks Moving Lower On Monday ↗

September 12, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Humacyte Earnings Perspective: Return On Invested Capital ↗

September 09, 2022

According to Benzinga Pro, during Q2, Humacyte (NASDAQ:HUMA) earned $36.87 million, a 285.9% increase from the preceding quarter. Humacyte also posted a total of $1.30 million in sales, a 458.37%...

Via Benzinga

Earnings Scheduled For August 12, 2022 ↗

August 12, 2022

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.